NCT00837356View on ClinicalTrials.gov

Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Congenital Bleeding DisorderHaemophilia A
Interventions
DRUG

Advate®

Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session

DRUG

turoctocog alfa

After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session

Trial Locations (7)

8091

Novo Nordisk Investigational Site, Zurich

10249

Novo Nordisk Investigational Site, Berlin

20124

Novo Nordisk Investigational Site, Milan

28046

Novo Nordisk Investigational Site, Madrid

30625

Novo Nordisk Investigational Site, Hanover

50134

Novo Nordisk Investigational Site, Florence

52621

Novo Nordisk Investigational Site, Tel Litwinsky

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY